Table of Contents:

1 Executive Summary
2 Market Introduction
2.1 Definition
2.2 Scope of the Study
2.3 List of Assumptions
2.4 Limitations
2.5 Market Structure
2.6 Key Takeaways
3 Market Insights
4 Research Methodology
4.1 Research Process
4.2 Primary Research
4.3 Secondary Research
4.4 Market Size Estimation
4.5 Top Down & Bottom Up Approach
4.6 Forecast Model
5 Market Dynamics
5.1 Introduction
5.2 Drivers
5.3 Acceptance of Advanced Medical Implants Devices by Patients
5.4 Increasing demand from various end-use applications
5.5 Growing Ageing World Population
5.6 Restraint
5.7 High cost of the devices
5.8 Opportunity
5.8.1 Rising usage in 3D printing technology
5.9 Trend
5.9.1 Expanding healthcare industry in emerging economies
6 Market Factor Analysis
6.1 Supply Chain Analysis
6.1.1 Raw Material Suppliers
6.1.2 Bioresorbable Polymers Manufacturers
6.1.3 Distribution Channel
6.1.4 End-User Industry
6.2 Porter's Five Forces Analysis
6.2.1 The Threat of New Entrants
6.2.2 Threat of Rivalry
6.2.3 Threat of Substitute
6.2.4 Bargaining Power of Supplier
6.2.5 Bargaining Power of Buyer
7 Global Bioresorbable Polymers Market, by Type
7.1 Introduction
7.2 Proteins
7.3 Polysachharides
7.4 Polyglycolic Acid (PGA)
7.5 Polylactic acid (PLA) & Derivatives
7.6 Polycaprolactone (PCL)
7.7 Polydioxanone (PDS)
7.8 Others
8 Global Bioresorbable Polymers Market, by Application
8.1 Introduction
8.2 Orthopedic
8.3 Drug Delivery
8.4 Others
9 Global Bioresorbable Polymers Market, by Region
9.1 Introduction
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Rest of Europe
?
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Rest of Asia Pacific
9.5 Latin America
9.5.1 Mexico
9.5.2 Brazil
9.5.3 Rest of Latin America
9.6 The Middle East and Africa
9.6.1 Turkey
9.6.2 G.C.C.
9.6.3 North Africa
9.6.4 Rest of Middle East and Africa
10 Competitive Landscape
10.1 Introduction
10.2 Market Strategy Analysis
10.3 Key Developments of Market Players
11 Company Profiles
11.1 Corbion NV
11.1.1 Company Overview
11.1.2 Financial Overview
11.1.3 Products Offerings
11.1.4 Key Developments
11.1.5 SWOT Analysis
11.1.6 Key Strategy
11.2 Evonik Industries AG
11.2.1 Company Overview
11.2.2 Financial Overview
11.2.3 Products Offerings
11.2.4 Key Developments
11.2.5 SWOT Analysis
11.2.6 Key Strategy
?
11.3 Foster Corporation
11.3.1 Company Overview
11.3.2 Financial Overview
11.3.3 Products Offerings
11.3.4 Key Developments
11.3.5 SWOT Analysis
11.3.6 Key Strategy
11.4 KLS Martin Group
11.4.1 Company Overview
11.4.2 Financial Overview
11.4.3 Products Offerings
11.4.4 Key Developments
11.4.5 SWOT Analysis
11.4.6 Key Strategy
11.5 Poly-Med Inc.
11.5.1 Company Overview
11.5.2 Financial Overview
11.5.3 Products Offerings
11.5.4 Key Developments
11.5.5 Key Strategy
11.6 DURECT Corporation
11.6.1 Company Overview
11.6.2 Financial Overview
11.6.3 Products Offerings
11.6.4 Key Developments
11.6.5 SWOT Analysis
11.6.6 Key Strategy
11.7 PCAS Group
11.7.1 Company Overview
11.7.2 Financial Overview
11.7.3 Products Offerings
11.7.4 Key Developments
11.7.5 SWOT Analysis
11.7.6 Key Strategy
?
11.8 Merck KGaA
11.8.1 Company Overview
11.8.2 Financial Overview
11.8.3 Products Offerings
11.8.4 Key Developments
11.8.5 SWOT Analysis
11.8.6 Key Strategy
11.9 Royal DSM NV
11.9.1 Company Overview
11.9.2 Financial Overview
11.9.3 Products Offerings
11.9.4 Key Developments
11.9.5 SWOT Analysis
11.9.6 Key Strategy
12 Conclusion
12.1 Key Findings